This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Carter V. Multz, MD

JAMA. 1981;246(6):674-675.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

VALUABLE as a slow-acting remission-inducing agent in the treatment of rheumatoid arthritis, penicillamine has gained progressive acceptance and increasing use throughout the world. Physicians should be alert to penicillamine as another agent capable of provoking cholestatic hepatitis, an infrequently described but important reaction.

Report of a Case

Therapy with penicillamine, 250 mg/ day, was started in a 53-year-old woman with rheumatoid arthritis of seven years' duration, which had been in severe exacerbation for three months. Because of the severity of her disease, the dosage was advanced rapidly to 500 mg/day after a week and 750 mg/day during the third week. Nausea, weakness, anorexia, and dark urine followed a week later. She was jaundiced and her liver edge was 3 cm below the right costal margin. She simultaneously experienced a marked amelioration of her rheumatoid disease. The penicillamine therapy was discontinued. A liver biopsy specimen and transhepatic cholangiogram demonstrated cholestatic hepatitis . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, O'Connor Hospital, San Jose, Calif, and the Institute of Clinical Medicine, Syntex Research, Palo Alto, Calif.

Footnotes
Reprint requests to Institute of Clinical Medicine, Syntex Research, 3401 Hillview Ave, Palo Alto, CA 94304 (Dr Multz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?